API | sofituzumab vedotin

sofituzumab vedotin Report issue

Biologics mAb ADC Experimental

AACT ChEMBL

Active Ingredient History

NOW

Sofituzumab vedotin is a monoclonal antibody designed for the treatment of ovarian cancer. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

None

sofituzumab vedotin

More Chemistry

Pharmacology

Mechanisms of Action:
- Mucin-16 (Homo sapiens) ^UniProt
- Mucin-16 (Homo sapiens) ^UniProt
Multi-specific: No
Payload: Monomethylauristatin E
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

anti-muc16 adc | dmuc5754a | rg-7458 | sofituzumab vedotin

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Pancreatic Neoplasms (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 1
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue